Any content you receive is for information purposes only. Always conduct your own research.
*Disseminated on Behalf of Medicus Pharma Ltd.
Paul Prescott Just Put (MDCX) Back On This Morning's Watchlist
—Wednesday, February 18, 2026
Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email.
Get (MDCX) On Your Radar While It's Still Early…
February 18, 2026
Get An Early Look Now | See Why (MDCX) Just Hit Our Morning Radar
Dear Reader, Most readers don't notice a healthcare story until it's already everywhere. Street Ideas looks earlier, when the evidence starts forming a chain: clinical updates, third-party validation, and a roadmap that expands the addressable therapeutic scope. That's what's happening here. The name sitting at the center of this developing setup is Medicus Pharma Ltd. (NASDAQ: MDCX). And this is just one of the reasons why (MDCX) is topping our watchlist this morning—Wednesday, February 18, 2026. But keep in mind, (MDCX) has less than 9M shares listed as available to the public, according to Market Watch. When companies have small floats like this, the potential exists for big moves if demand begins to shift. Right now, (MDCX) is sitting below $1.25 and appears to be flying under the radar of many screens. Last week, (MDCX) made an approximate 24% move, from $.935 on February 11, to $1.16 on February 13, putting it above its 5-day moving average. Jason McCarthy, Senior Managing Director, Head of Biotechnology Research at Maxim Group set a $12 target on (MDCX), which suggests 1,100% upside potential from its recent $1 range. 
What matters most is what sits underneath those numbers—and why (MDCX) is starting to look less like a sleeper and more like a name readers will be hearing a lot more about. The New Face of Precision Biotech
Medicus Pharma Ltd. (NASDAQ: MDCX) is not your typical clinical-stage company; it is a precision-guided biopharmaceutical firm that has spent the last year aggressively diversifying its pipeline to address massive unmet medical needs. While many in the sector chase incremental improvements, (MDCX) is focused on "disruptive" delivery systems—like dissolvable microneedle patches—and next-generation hormone therapies that prioritize patient safety and non-invasive care. The company operates across three continents and has recently transformed its profile from a single-asset developer into a multi-asset powerhouse. This evolution was punctuated by the acquisition of Antev Limited, which brought the $6B potential of the Teverelix program under the (MDCX) umbrella. Led by Executive Chairman and CEO Dr. Raza Bokhari, the management team is composed of industry veterans with a track record of taking assets from the lab through the complex regulatory hurdles of the FDA. A Tale of Two Blockbuster Pipelines To understand why (MDCX) is commanding such significant attention right now, one must look at its two core pillars: SkinJect and Teverelix. 1. The SkinJect™ Platform: Replacing the Scalpel The SkinJect platform is a patented, dissolvable microneedle array (D-MNA) designed to treat basal cell carcinoma (BCC)—the most common form of skin cancer—without the need for surgery. For the millions of patients diagnosed with BCC annually, the standard of care often involves invasive cutting that can leave permanent scarring. (MDCX) is aiming to replace the scalpel with a localized patch that delivers treatment directly into the lesion. 
The program is currently in the late stages of a U.S. Phase 2 clinical trial (SKNJCT-003), which has fully enrolled 90 patients. This is a critical point for the company, as "decision-grade" topline results are expected in Q1 2026. Early interim data showed a 60% clinical clearance rate, a safety validation that has already led to the FDA granting a streamlined 505(b)(2) regulatory pathway, potentially shaving years off the time to market. 2. Teverelix: Solving the Cardiovascular Crisis in Oncology The second pillar, Teverelix, is a next-generation GnRH antagonist targeting a massive $6B total addressable market. Its primary focus is on advanced prostate cancer patients who also face a high risk of heart disease—a group that represents roughly 30% of all prostate cancer deaths. Unlike existing treatments that can cause dangerous "testosterone flares" or increase cardiovascular strain, Teverelix is designed to suppress hormones rapidly and safely. 
Just last week, on February 10, 2026, the company received FDA "Study May Proceed" clearance to begin a Phase 2b study for these high-risk patients. This follows a major economic win on January 22, 2026, where the company slashed its royalty obligations from 4% to 2%, significantly increasing the long-term value of the asset for shareholders. The AI-Enabled Strategy: Modernizing Clinical Trials
One of the most distinctive aspects of (MDCX) is its forward-thinking use of technology. In late 2025, the company announced a strategic engagement with Reliant AI, a decision-intelligence firm founded by former researchers from Google Brain and DeepMind. This partnership is not just a buzzword; it is a functional tool being used to build an AI-driven clinical data analytics platform. By using advanced machine learning for site selection and patient stratification, (MDCX) aims to execute its trials with "capital-efficient" precision. This tech-heavy approach is intended to reduce the high failure rates and ballooning costs typically associated with development. Expanding the Horizon: Women's Health and Compassionate Use Beyond oncology, (MDCX) is proving the versatility of its science. Recent data demonstrated that Teverelix can achieve rapid hormone suppression while maintaining stable bone turnover in women—a critical safety milestone. This clears a path for the company to enter the $2B+ endometriosis market, adding yet another major revenue stream to the pipeline. Furthermore, the company's commitment to patient advocacy is evident through its collaboration with the Gorlin Syndrome Alliance (GSA). Together, they are pursuing an Expanded Access IND Program with the FDA. This would allow patients with rare genetic conditions who suffer from multiple, inoperable skin cancers to access the SkinJect patch under physician supervision, potentially providing a lifeline for those with no other options while gathering critical "real-world" safety data. Global Expansion and the Nasdaq Spotlight
The company's reach is truly global. While the U.S. remains its primary market, (MDCX) is currently conducting Phase 2 studies in the UAE through a partnership with the Cleveland Clinic Abu Dhabi. This global footprint not only accelerates enrollment but also positions the company for international licensing deals. All of this momentum culminated on January 22, 2026, when Dr. Raza Bokhari rang the Opening Bell at Nasdaq. This ceremony wasn't just a celebration of a one-year listing anniversary; it was a public declaration of the company's arrival as a serious player in the biotech space. 7 Factors Putting (MDCX) On This Morning's Early Watchlist
—Wednesday, February 18, 2026…
1. Analyst Coverage: a $12 target from Maxim Group's Jason McCarthy places (MDCX) well above its recent $1 range and suggests around 1,100% upside potential.
2. Recent Momentum: after moving approximately 24% from $0.935 on February 11 to $1.16 on February 13, (MDCX) pushed back above its 5-day moving average.
3. Small Float: with fewer than 9M shares listed as publicly available, (MDCX)'s small float could see the potential for big moves if demand begins to shift. 4. Dual Pipeline: beyond a single asset profile, (MDCX) now advances both SkinJect and Teverelix following the acquisition of Antev Limited, expanding its clinical scope. 5. Near-Term Data: with 90 patients fully enrolled in its U.S. Phase 2 SKNJCT-003 study and topline results expected in Q1 2026, (MDCX) is approaching a defined clinical readout window. 6. AI Integration: through its engagement with Reliant AI, (MDCX) is applying machine-learning tools to clinical site selection and patient stratification to improve trial execution. 7. FDA Momentum: February 10, 2026 brought "Study May Proceed" clearance for a Phase 2b trial, giving (MDCX) regulatory alignment in advanced prostate cancer patients with high cardiovascular risk. Get (MDCX) On Radar While It's Still Early…
(MDCX) is one of those rare setups where multiple signals line up at the same time: a small float under 9M shares, fresh momentum that has already pushed it back above the 5-day moving average, and formal analyst coverage that suggests 1,100% upside potential.
More importantly, the story is supported by substance—two active programs (SkinJect and Teverelix), FDA "Study May Proceed" clearance for a Phase 2b trial in a high-need prostate cancer segment, and a clear near-term readout window with SKNJCT-003 now fully enrolled and topline data expected in Q1 2026. Add in the Reliant AI engagement aimed at sharper site selection and patient stratification, and it becomes clear this is not just noise—this is a company executing on multiple fronts with measurable milestones ahead. (MDCX) is the one we're watching first thing this morning. Check out (MDCX) while it's still early. And watch for my next update—it might be coming within the next hour. Sincerely, Paul Prescott
Co-Founder & Managing Editor
Street Ideas Newsletter
| 
No comments:
Post a Comment